untitled h1
10.0 references

1. Champlin, R.E., *T-cell depletion for bone marrow transplantation: effects on graft rejection,*
graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treatment & Research, 1990. 50: p. 99-111.  
2. Giralt, S.A. and H.J. Kolb, *Donor lymphocyte infusions.* Current Opinion in Oncology, 1996.  
8(2): p. 96-102.  
3. Martin, P.J., et al., *Graft failure in patients receiving T cell-depleted HLA-identical allogeneic* marrow transplants. Bone Marrow Transplantation, 1988. 3(5): p. 445-56.  
4. Giralt, S., et al., *Engraftment of allogeneic hematopoietic progenitor cells with purine analogcontaining chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.*
Blood, 1997. 89(12): p. 4531-6.  
5. Slavin, S., et al., *Nonmyeloablative stem cell transplantation and cell therapy as an alternative to* conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998. 91(3): p. 756-63.  
6. Cheson, B.D., *Infectious and immunosuppressive complications of purine analog therapy.* Journal of Clinical Oncology, 1995. 13(9): p. 2431-48.  
7. Williamson, L.M., et al., Fludarabine treatment and transfusion-associated graft-versus-host disease. [letter; comment.]. Lancet, 1996. 348(9025): p. 472-3.  
8. Khouri, I.F., et al., Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. [see comments.]. Journal of Clinical Oncology, 1998. 16(8): p. 2817-24.  
9. Mosmann, T.R., et al., *Two types of murine helper T cell clone. I. Definition according to profiles* of lymphokine activities and secreted proteins. Journal of Immunology, 1986. 136(7): p. 2348-57.  
10. Ferrara, J.L. and H.J. Deeg, *Graft-versus-host disease. [see comments.].* New England Journal of Medicine, 1991. 324(10): p. 667-74.  
11. Fowler, D.H., et al., *Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine* graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. Journal of Immunology, 1994. 152(3): p. 1004-13.  
12. Fowler, D.H., et al., *Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versushost disease without impairing allogeneic engraftment in sublethally irradiated mice.* Blood, 1994. 84(10): p. 3540-9.  
13. Petrus, M.J., et al., *An immunoablative regimen of fludarabine and cyclophosphamide prevents* fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biology of Blood
& Marrow Transplantation, 2000. 6(2A): p. 182-9.  
14. Briones, J., A. Pereira, and I. Alcorta, Transfusion-associated graft-versus-host disease (TAGVHD) in fludarabine-treated patients: is it time to irradiate blood component? [letter; comment.]. British Journal of Haematology, 1996. 93(3): p. 739-41.  
15. Fenchel, K., et al., *Clinical experience with fludarabine and its immunosuppressive effects in* pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leukemia & Lymphoma, 1995. 18(5-6): p. 485-92.  
16. Wilson, W.H., et al., *EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory nonHodgkin's lymphoma.* Journal of Clinical Oncology., 1993. 11(8): p. 1573-82.  
17. Wilson, W.H., et al., Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 2002. 99(8): p. 2685-2693.  
18. Gutierrez, M., et al., *Role of a doxorubicin-containing regimen in relapsed and resistant* lymphomas: an 8-year follow-up study of EPOCH. Journal of Clinical Oncology., 2000. 18(21):
p. 3633-42.  
19. O'Brien, S., et al., Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. [see comments.]. Blood, 1993. 82(6): p. 1695-700.  
20. Zaja, F., et al., *Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant* patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. European Journal of Haematology, 1997. 59(5): p. 327-8.  
21. McConkey, D.J., et al., Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. Journal of Immunology, 1996. 156(7): p. 2624-30.  
22. Wilson, W.H., et al., *The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a* preliminary report of dose-adjusted EPOCH-R. Seminars in Oncology., 2002. 29(1 Suppl 2): p.  
41-7.  
23. Vose, J.M., et al., Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. J Clin Oncol, 2001. 19(2): p. 389-397.  
24. Coiffier, B., et al., *CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly* Patients with Diffuse Large-B-Cell Lymphoma. N Engl J Med, 2002. 346(4): p. 235-242.  
25. Khouri, I.F., et al., *Nonablative allogeneic hematopoietic transplantation as adoptive* immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 2001. 98(13): p. 3595-3599.  
26. Ratanatharathorn, V., *Anti-CD20 chimeric monoclonal antibody treatment of refractory immunemediated thrombocytopenia in a patient with chronic graft-versus-host disease.* Annals of Internal Medicine, 2000. 133(4): p. 275-9.  
27. Champlin, R., et al., *Reinventing bone marrow transplantation. Nonmyeloablative preparative* regimens and induction of graft-vs-malignancy effect. Oncology (Huntington), 1999. 13(5): p.  
621-8; discussion 631.  
28. Storb, R., et al., Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood, 1988. 71(2): p.  
293-8.  
29. Storb, R., et al., *Methotrexate and cyclosporine compared with cyclosporine alone for* prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New England Journal of Medicine, 1986. 314(12): p. 729-35.  
30. Storb, R., et al., Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood, 1989. 73(6): p. 1729-34.  
31. Yau, J.C., et al., An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. American Journal of Hematology., 1991.  
38(4): p. 288-92.  
32. Przepiorka, D., et al., *Tacrolimus and minidose methotrexate for prevention of acute graft-versushost disease after matched unrelated donor marrow transplantation.* Blood., 1996. 88(11): p.  
4383-9.  
33. Yau, J.C., et al., Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplantation, 1990. 5(4): p. 269-72.  
34. Atkinson, K. and K. Downs, Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplantation, 1995. 16(6): p. 755-8.  
35. Giralt, S., et al., *Melphalan and purine analog-containing preparative regimens: reducedintensity conditioning for patients with hematologic malignancies undergoing allogeneic* progenitor cell transplantation. Blood, 2001. 97(3): p. 631-7.  
36. Wasch, R., et al., *Rapid achievement of complete donor chimerism and low regimen-related* toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplantation, 2000. 26(3): p. 243-50.  
37. Corradini, P., et al., Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002. 99(1): p. 75-82.  
38. Childs, R., et al., *Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem* cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 1999.  
94(9): p. 3234-41.  
39. Hakim, F.T., et al., Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood, 1997. 90(9): p.  
3789-98.  
40. Cheson, B.D., et al., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. [erratum appears in J Clin Oncol 2000 Jun;18(11):2351.]. Journal of Clinical Oncology, 1999. 17(4): p. 1244.  
41. Kostakoglu, L. and S.J. Goldsmith, *Fluorine-18 fluorodeoxyglucose positron emission* tomography in the staging and follow-up of lymphoma: is it time to shift gears? European Journal of Nuclear Medicine, 2000. 27(10): p. 1564-78.  
42. Mackall, C.L., *T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review.*
Oncologist, 1999. 4(5): p. 370-8.  
43. Fry, T.J. and C.L. Mackall, *Interleukin-7: from bench to clinic.* Blood, 2002. 99(11): p. 38923904.  
44. Bolotin, E., et al., Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood, 1996. 88(5): p. 1887-1894.  
45. Fry, T.J., et al., *A potential role for interleukin-7 in T-cell homeostasis.* Blood, 2001. 97(10): p.  
2983-2990.  
46. Napolitano, L.A., et al., *Increased production of IL-7 accompanies HIV-1-mediated T-cell* depletion: implications for T-cell homeostasis. Nature Medicine., 2001. 7(1): p. 73-9.  
47. Abdul-Hai, A., et al., *Stimulation of immune reconstitution by interleukin-7 after syngeneic bone* marrow transplantation in mice. [erratum appears in Exp Hematol 1996 Nov;24(13):1540.].  
Experimental Hematology, 1996. 24(12): p. 1416-22.  
48. Mackall, C.L., et al., IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood, 2001. 97(5): p. 1491-7.  
49. Alpdogan, O., et al., *Administration of interleukin-7 after allogeneic bone marrow* transplantation improves immune reconstitution without aggravating graft-versus-host disease.  
Blood, 2001. 98(7): p. 2256-65.  
50. Sinha, M.L., et al., *Interleukin 7 worsens graft-versus-host disease.* Blood, 2002. 100(7): p. 26422649.  
51. Waldmann, T., *The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes:*
implications for the immunotherapy of rheumatological diseases. Arthritis Res, 2002. **4 Suppl 3**:
p. S161-7.  
52. Neely, G.G., et al., Lipopolysaccharide-stimulated or granulocyte-macrophage colonystimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J Immunol, 2001. 167(9): p. 5011-7.  
53. Musso, T., et al., Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood, 1999. 93(10): p. 3531-9.  
54. Kumaki, S., et al., *Prolonged secretion of IL-15 in patients with severe forms of acute graftversus-host disease after allogeneic bone marrow transplantation in children.* Int J Hematol, 1998. 67(3): p. 307-12.  
55. Thulesen, S., et al., Interleukin 15 is a growth factor for human thymocytes with preferential effect on CD8(+)cells. Cytokine, 2000. 12(6): p. 751-5.  
56. Tan, J.T., et al., Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med, 2002.  
195(12): p. 1523-32.  
57. Zhang, X., et al., Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity, 1998. 8(5): p. 591-9.  
58. Goldrath, A.W., et al., *Cytokine requirements for acute and Basal homeostatic proliferation of* naive and memory CD8+ T cells. J Exp Med, 2002. 195(12): p. 1515-22.  
59. Kennedy, M.K., et al., Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med, 2000. 191(5): p. 771-80.  
60. Borthwick, N.J., et al., *Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor* gamma chain signalling cytokines and type I IFN, and increases susceptibility to activationinduced apoptosis. Int Immunol, 2000. 12(7): p. 1005-13.  
61. Rutella, S., et al., Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol, 2001. 29(12): p. 1503-16.  
62. Roberts, A.I., et al., *NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL*
in the tissue microenvironment. J Immunol, 2001. 167(10): p. 5527-30.  
63. Groh, V., et al., *Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC*
induced on virus-infected cells. Nat Immunol, 2001. 2(3): p. 255-60.  
64. Cooper, M.A., T.A. Fehniger, and M.A. Caligiuri, *The biology of human natural killer-cell* subsets. Trends Immunol, 2001. 22(11): p. 633-40.  
65. Ruggeri, L., et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002. 295(5562): p. 2097-100.  
66. Murphy, W.J., et al., Immunobiology of natural killer cells and bone marrow transplantation:
merging of basic and preclinical studies. Immunol Rev, 2001. 181: p. 279-89.  
67. Parrish-Novak, J., et al., *Interleukin 21 and its receptor are involved in NK cell expansion and* regulation of lymphocyte function. Nature, 2000. 408(6808): p. 57-63.  
68. Popplewell, L.L. and S.J. Forman, *Is there an upper age limit for bone marrow transplantation?*
Bone Marrow Transplantation., 2002. 29(4): p. 277-84.  
69. Crawford, S.W. and L. Fisher, Predictive value of pulmonary function tests before marrow transplantation. [see comments.]. Chest, 1992. 101(5): p. 1257-64.  
70. Calhoun, D.A., et al., *Granulocyte colony-stimulating factor is present in human milk and its* receptor is present in human fetal intestine. Pediatrics, 2000. 105(1): p. e7.  
71. Bernstein, H.M., D.A. Calhoun, and R.D. Christensen, *Use of myeloid colony-stimulating factors* in neonates with septicemia. Current Opinion in Pediatrics, 2002. 14(1): p. 91-4.  
72. Anderlini, P., et al., Allogeneic blood stem cell transplantation: considerations for donors. [see comments.]. Blood, 1997. 90(3): p. 903-8.  
73. Spitzer, T.R., *Engraftment syndrome following hematopoietic stem cell transplantation.* Bone Marrow Transplantation, 2001. 27(9): p. 893-8.  
74. Glucksberg, H., et al., Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 1974. 18(4): p. 295-304.  
75. Bowden, R.A., et al., *A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV)*
seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. [see comments.]. Blood, 1995. 86(9): p. 3598-603.  
76. Wolfe, J.L., et al., *Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride,*
and etoposide in 0.9% sodium chloride injection. American Journal of Health-System Pharmacy, 1999. 56(10): p. 985-9.  
77. Lyytikainen, O., et al., *Late onset Pneumocystis carinii pneumonia following allogeneic bone* marrow transplantation. Bone Marrow Transplantation, 1996. 17(6): p. 1057-9.  
78. Vasconcelles, M.J., et al., *Aerosolized pentamidine as pneumocystis prophylaxis after bone* marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biology of Blood & Marrow Transplantation, 2000. 6(1): p. 35-43.  
79. Girard, P.M., et al., Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. New England Journal of Medicine, 1993. 328(21): p. 1514-20.  
80. Golden, J.A., et al., A randomized comparison of once-monthly or twice-monthly high-dose aerosolized pentamidine prophylaxis. Chest, 1993. 104(3): p. 743-50.  
81. Rizzardi, G.P., et al., Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. Journal of Infection, 1995. 31(2): p. 99-105.  
82. Meyers, B., F. Borrego, and G. Papanicolaou, Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Liver Transpl, 2001. 7(8): p. 750-1.  
83. Chan, C., et al., Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis, 1999. 180(2): p. 369-76.  
84. El-Sadr, W.M., et al., *Atovaquone compared with dapsone for the prevention of Pneumocystis* carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med, 1998. 339(26): p. 1889-95.  
85. Colby, C., et al., *A prospective randomized trial comparing the toxicity and safety of atovaquone* with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant, 1999. 24(8): p.  
897-902.  
86. Marr, K.A., et al., Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term followup of a randomized, placebo-controlled trial. Blood, 2000. 96(6): p. 2055-61.  
87. Slavin, M.A., et al., *Efficacy and safety of fluconazole prophylaxis for fungal infections after* marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis, 1995. 171(6): p. 1545-52.  
88. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med, 1989. 86(6 Pt 1): p. 668-72.  
89. Walsh, T.J., et al., Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 2002. 346(4):
p. 225-34.  
90. *Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant* recipients. MMWR Recomm Rep, 2000. 49(RR-10): p. 1-125, CE1-7.  
91. Kanda, Y., et al., Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 2001. 28(7): p.  
689-92.  
92. Steer, C.B., et al., Varicella-zoster infection after allogeneic bone marrow transplantation:
incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant, 2000. 25(6): p. 657-64.  
93. Koc, Y., et al., *Varicella zoster virus infections following allogeneic bone marrow* transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant, 2000. 6(1): p. 44-9.  
94. Martin, D.F., et al., *A controlled trial of valganciclovir as induction therapy for cytomegalovirus* retinitis. N Engl J Med, 2002. 346(15): p. 1119-26.  
95. Dykewicz, C.A., *Summary of the Guidelines for Preventing Opportunistic Infections among* Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis, 2001. 33(2): p. 139-44.  
96. Kulkarni, S., et al., *Chronic graft versus host disease is associated with long-term risk for* pneumococcal infections in recipients of bone marrow transplants. Blood, 2000. 95(12): p. 36836.  
97. Picardi, M., C. Selleri, and B. Rotoli, Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations. Bone Marrow Transplant, 1999. 24(2): p. 173-7.  
98. Vance, E., et al., Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant, 1998. 22(8): p. 735-41.  
99. Metcalf, J.P., et al., *Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage* associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. American Journal of Medicine, 1994. 96(4): p. 327-34.